Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years-Reference-Cited by-同舟云学术

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years

Published:2009-08 Issue:2 Volume:132 Page:166-173
ISSN:1521-6616
Container-title:Clinical Immunology
language:en
Short-container-title:Clinical Immunology

Author:

Herold Kevan C.,Gitelman Stephen,Greenbaum Carla,Puck Jennifer,Hagopian William,Gottlieb Peter,Sayre Peter,Bianchine Peter,Wong Emelita,Seyfert-Margolis Vicki,Bourcier Kasia,Bluestone Jeffrey A.

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference22 articles.

1. A single course of anti-CD3 monoclonal antibody hOKT3{gamma}1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes;Herold;Diabetes,2005

2. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus;Herold;N. Engl. J. Med.,2002

3. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes;Keymeulen;N. Engl. J. Med.,2005

4. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala);Herold;J. Clin. Invest.,2003

5. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes;Belghith;Nat. Med.,2003

Cited by 176 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From pre-clinical efficacy to promising clinical trials that delay Type 1 diabetes;Pharmacological Research;2024-10

2. Teplizumab’s immunomodulatory effects on pancreatic β-cell function in type 1 diabetes mellitus;Clinical Diabetes and Endocrinology;2024-08-10

3. Revolutionizing type 1 diabetes management: Exploring oral insulin and adjunctive treatments;Biomedicine & Pharmacotherapy;2024-07

4. Efficacy of teplizumab for treatment of type 1 diabetes: A meta‐analysis of randomized controlled trials;Diabetes/Metabolism Research and Reviews;2024-05

5. Role of Teplizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Managing Newly Diagnosed Type 1 Diabetes: An Updated Systematic Review and Meta-Analysis;Endocrine Practice;2024-05